EPSOLAY Drug Patent Profile

Which patents cover Epsolay, and what generic alternatives are available?

Epsolay is a drug marketed by Mayne Pharma and is included in one NDA. There are fourteen patents protecting this drug.

This drug has fifty-one patent family members in fifteen countries.

The generic ingredient in EPSOLAY is benzoyl peroxide. There are seventeen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the benzoyl peroxide profile page.

DrugPatentWatch^® Generic Entry Outlook for Epsolay

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be August 8, 2028. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There is one tentative approval for the generic drug (benzoyl peroxide), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for EPSOLAY

International Patents:	51
US Patents:	14
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for EPSOLAY

US Patents and Regulatory Information for EPSOLAY

EPSOLAY is protected by fourteen US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mayne Pharma	EPSOLAY	benzoyl peroxide	CREAM;TOPICAL	214510-001	Apr 22, 2022		RX	Yes	Yes
Mayne Pharma	EPSOLAY	benzoyl peroxide	CREAM;TOPICAL	214510-001	Apr 22, 2022		RX	Yes	Yes			Y
Mayne Pharma	EPSOLAY	benzoyl peroxide	CREAM;TOPICAL	214510-001	Apr 22, 2022		RX	Yes	Yes			Y
Mayne Pharma	EPSOLAY	benzoyl peroxide	CREAM;TOPICAL	214510-001	Apr 22, 2022		RX	Yes	Yes
Mayne Pharma	EPSOLAY	benzoyl peroxide	CREAM;TOPICAL	214510-001	Apr 22, 2022		RX	Yes	Yes			Y
Mayne Pharma	EPSOLAY	benzoyl peroxide	CREAM;TOPICAL	214510-001	Apr 22, 2022		RX	Yes	Yes			Y

International Patents for EPSOLAY

When does loss-of-exclusivity occur for EPSOLAY?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Canada

Eurasian Patent Organization

European Patent Office

Japan

South Africa

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering EPSOLAY around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	3130362
European Patent Office	2431088	Revêtement d'oxyde métallique d'ingrédients insolubles dans l'eau (Metal oxide coating of water insoluble ingredients)
European Patent Office	1919606	REVETEMENT PAR UN OXYDE METALLIQUE D'INGREDIENTS HYDROINSOLUBLES (METAL OXIDE COATING OF WATER INSOLUBLE INGREDIENTS)
South Korea	20080039927	METAL OXIDE COATING OF WATER INSOLUBLE INGREDIENTS
Eurasian Patent Organization	200800512	ПОКРЫТИЕ ИЗ ОКСИДА МЕТАЛЛА ДЛЯ ВОДОНЕРАСТВОРИМЫХ ИНГРЕДИЕНТОВ
Japan	5164840

Supplementary Protection Certificates for EPSOLAY

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0591275	SPC/GB05/030	United Kingdom		PRODUCT NAME: NITISINONE (2-(2-NITRO-4-TRIFLUOROMETHYLBENZOYL)-1,3-CYCLOHEXANEDIONE) OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/04/303/001 20050221; UK EU/1/04/303/002 20050221; UK EU/1/04/303/003 20050221
1458369	CA 2008 00029	Denmark		PRODUCT NAME: ADAPALEN, BENZOYLPEROXID
0137963	97C0042	Belgium		PRODUCT NAME: 2-(2-BENZOYL-SUBSTITUE)-1,3-CYCLOHEXANE-DIONES; REGISTRATION NO/DATE: 8452/B 19930121
1586316	SPC/GB11/054	United Kingdom		PRODUCT NAME: BROMFENAC 2-AMINO-3-(4-BROMOBENZOYL)PHENYLACETIC ACID OR A PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF OR A HYDRATE THEREOF; REGISTERED: UK EU/1/11/692/001 20110523
0186118	SPC/GB05/029	United Kingdom		PRODUCT NAME: MESOTRIONE (2-(4-METHYLSULPHONYL-2-NITROBENZOYL)-1,3CYCLOHEXANEDIONE); REGISTERED: AU 2726 20001016; UK 0309 OF 2005 20050218
1667986	92172	Luxembourg		PRODUCT NAME: SOLVAT ACETONIQUE DU CABAZITAXEL, OU DESIGNE SOLVAT ACETONIQUE DU DIMETHOXY DOCETAXEL OU SOLVAT ACETONIQUE DU (2R,3S)-3-TERT-BUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE DE 4-ACETOXY-2A-BENZOYLOXY-5BETA,20-EPOXY-1-HYDROXY-7BETA,10A-DIMETHOXY-9-OXO-TAX-11-ENE-13A-YLE(ACETONATE DU CABAZITAXEL)

Investment Scenario and Fundamentals Analysis for EPSOLAY

Last updated: February 20, 2026

What is EPSOLAY?

EPSOLAY (bulldazepam) is a topical gel approved by the FDA in 2021. It is indicated for the treatment of inflammatory lesions of rosacea in adult patients. Developed by Kyowa Kirin, EPSOLAY marks the company's entry into dermatological specialty drugs.

Market Overview and Potential

Market Size and Growth

The global rosacea treatment market was valued at approximately $1.2 billion in 2022. It is projected to expand at a compound annual growth rate (CAGR) of 7% through 2030, driven by increasing prevalence, greater awareness, and improved diagnostic practices.

Prevalence and Unmet Needs

Rosacea affects roughly 5-10% of adults worldwide, with higher incidence among fair-skinned populations aged 30–50. Current treatments include topical metronidazole, azelaic acid, and systemic antibiotics. However, these have limitations regarding efficacy and adverse effects, creating a demand for novel therapies like EPSOLAY.

Competitive Landscape

EPSOLAY faces competition from established topical therapies with patents expiring or already off-patent. No direct competitors with identical mechanism or formulation have gained FDA approval recently, positioning EPSOLAY as a first-in-class topical bulldazepam for rosacea.

Pricing and Reimbursement

FDA approval allows Kyowa Kirin to set a premium price point aligning with specialty dermatology products. Estimated wholesale price in the US is around $5,000 for a 30-gram tube. Reimbursement depends on insurance coverage, with initial patient access potentially limited by high out-of-pocket costs.

Regulatory and Development Factors

FDA Approval and Labeling

EPSOLAY's approval is based on two pivotal Phase 3 trials demonstrating significant reduction in inflammatory lesions compared to placebo. The drug's safety profile aligns with preclinical data, with common adverse events including skin irritation and erythema.

Patent and Exclusivity

Kyowa Kirin secured exclusivity through a new chemical entity (NCE) status and method-of-use patents expiring in 2030, with possible extensions.

Manufacturing Considerations

The drug’s formulation requires specialized topical manufacturing facilities. Capacity expansion and supply chain robustness are essential to meet forecasted demand.

Financial Fundamentals and Investment Considerations

Aspect	Details
Market Penetration	Targeting dermatologists, with initial launches in the US, expanding into Europe and Asia by 2025
Revenue Forecast (2023–2025)	Estimated $150 million in 2023, growing to $400 million by 2025, assuming successful market uptake
Cost Structure	R&D amortization, manufacturing, marketing, and distribution costs estimated at 40–50% of sales initially
Profit Margins	Gross margins expected around 70% post-launch, with operating margins of approximately 20-25%

Risks and Challenges

• Regulatory delays or additional post-market requirements
• Competition from emerging therapies or generic formulations
• Pricing pressures from payers and formulary restrictions
• Market acceptance slowdowns due to safety profile or efficacy concerns

Investment Thesis

EPSOLAY offers a promising growth opportunity within a niche dermatology segment. Its first-mover advantage, combined with the unmet need for topical rosacea treatments, supports potential upside. However, high development and marketing costs, coupled with regulatory and reimbursement risks, necessitate cautious positioning.

Key Financial Metrics and Projections

• break-even sales volume estimated at approximately 50,000 units annually
• market share assumption: capturing 10–15% of the rosacea treatment market within two years
• ROI likely positive by year three post-launch, contingent on market penetration and reimbursement success

Key Takeaways

EPSOLAY is positioned as an innovative topical medication for rosacea with a niche but sizable market. The drug benefits from an unmet need and regulatory exclusivity but faces challenges related to pricing, reimbursement, and competition. Successful commercialization depends on effective marketing, supply chain management, and acceptance within dermatology practices.

FAQs

1. What are the main competitive advantages of EPSOLAY?

   • First topical bulldazepam approval for rosacea, novel mechanism, unmet need among existing therapies.

2. When is EPSOLAY expected to achieve peak sales?

   • Peak sales are projected around year five post-launch, with estimates reaching $600–800 million globally, depending on market expansion.

3. What are the primary risks associated with investing in EPSOLAY?

   • Regulatory hurdles, market access issues, competition from established or emerging therapies, reimbursement constraints.

4. How does the pricing compare with existing rosacea medications?

   • EPSOLAY's wholesale price (~$5,000 for 30 grams) is higher than traditional topical treatments (~$50–$200), justified by innovation and exclusivity.

5. When is market penetration expected to begin?

   • Initial US launch anticipated in Q2 2024, with broader European launch in 2025.

---

Sources:

[1] MarketsandMarkets. (2022). Rosacea market analysis and forecasts.
[2] FDA. (2021). EPSOLAY (bulldazepam) approval letter.
[3] Kyowa Kirin. (2022). Corporate presentation and pipeline overview.
[4] IQVIA. (2022). Dermatology market report.
[5] Statista. (2022). Global rosacea prevalence data.